Arvalus receives 2.2€ Million funding from DZIF

Written By Christian Brandstetter

We have secured a €2.2 million grant of non-dilutive funding from the Deutsches Zentrum für Infektionsforschung (DZIF).

This funding will enable us to advance to a Phase 1 clinical trial for our Arvalus live biotherapeutic product (LBP). We remain committed to driving scientific research, collaborating with industry partners, and expanding our team as we push forward in the fight against infections and antimicrobial resistance.

We sincerely thank DZIF for their confidence in our technology and team and look forward to continuing this valuable collaboration. A heartfelt thank you to our partners for their trust and shared vision in combating infections and antimicrobial resistance through the microbiome.

Special thanks to the Helmholtz Centre for Infection Research, Helmoltz Association, INCATE and many more for their ongoing support!

#funding #microbiome #AMR #DZIF #LBP

Christian Brandstetter https://www.arvalus-therapeutics.com
Next

Lisa Osbelt-Block on television as part of the 3sat Talkshow “Scobel - Biotop Mensch”